With the latest batch of quarterly operating results behind most companies and rising economic anxiety across the globe, it's likely that most stocks will be driven by macro and sector-specific forces in the near term. But that may not be true for biodiesel producer Renewable Energy Group (NASDAQ: REGI) and pharma giant Novo Nordisk (NYSE: NVO).
Events taking place this September have the potential to leave a lasting mark on the two businesses. Renewable Energy Group's long-term future -- and a pending $370 million windfall -- could be heavily influenced by Congress returning to session after its summer recess. Meanwhile, U.S. regulators will hand down a decision on Novo Nordisk's most important drug candidate, oral semaglutide, by the end of the month. Some analysts expect the drug to deliver peak annual sales of $5 billion, which would inject much-needed growth into the pharma giant.
Here's why investors looking for a little excitement should watch these two stocks this September.